SCHEMBL18790713

SCHEMBL18790713

CC(C)(C)OC(=O)N1CCN(c2cc(Cl)cnn2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 2/20 0.49
▸ SKP1 P63208 2/20 0.49
▸ SKP2 Q13309 2/20 0.49
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ SUV39H2 Q9H5I1 1/20 0.46
▸ GPR119 Q8TDV5 2/20 0.46
▸ MAP4K4 O95819 1/20 0.45
▸ CNR1 P21554 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ RET P07949 1/20 0.44
▸ ADK P55263 1/20 0.44
▸ SMARCA2 P51531 1/20 0.44
▸ SMARCA4 P51532 1/20 0.44
▸ PBRM1 Q86U86 1/20 0.44
▸ STS P08842 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38663361 1.00 CKS1B (0.49) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL15114941 0.84 CKS1B (0.48) CKS1BSKP1SKP2SUV39H2GPR119
SCHEMBL4425180 0.82 TRPV1 (0.51) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL4309116 0.82 CKS1B (0.55) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL38664512 0.81 SMARCA2 (0.48) MEN1KMT2AGPR119CNR1SMARCA2
SCHEMBL3164551 0.80 GPR119 (0.54) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL30962028 0.80 MAPT (0.49) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL27717174 0.79 GPR119 (0.53) CKS1BSKP1SKP2GPR119MAP4K4
SCHEMBL1686074 0.79 GPR119 (0.52) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL32129014 0.79 GPR119 (0.52) CKS1BSKP1SKP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025054132-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-03-13 — — WO disclosed
EP-3381904-B1 NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2021-07-28 — — EP disclosed
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-07-21 — — US disclosed
WO-2017069226-A1 NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2017-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound REN, NR3C2, NR5A1 CKS1B 840/4885SKP1 1872/4885SKP2 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback